Xu T, Wang X, Xin Y, Wang Z, Gong J, Zhang X, Li Y, Ji C, Sun Y, Zhao F, et al: Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysis. Cancer Res Treat. 55:626–635. 2023. View Article : Google Scholar :

Torka P, Groman A, Wong J, Nichols J, Kader A, Mavis C, Anampa-Guzmán A, Sait SJ, Block A, Przespolewski E, et al: Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. Blood Adv. 7:1146–1155. 2023. View Article : Google Scholar

Yin Q, Shen J, Zhang Z, Yu H and Li Y: Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Deliv Rev. 65:1699–1715. 2013. View Article : Google Scholar : PubMed/NCBI

Ruan T, Liu W, Tao K and Wu C: A review of research progress in multidrug-resistance mechanisms in gastric cancer. Onco Targets Ther. 13:1797–1807. 2020. View Article : Google Scholar : PubMed/NCBI

Lu C, Wei Y, Wang X, Zhang Z, Yin J, Li W, Chen L, Lyu X, Shi Z, Yan W and You Y: DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 19:282020. View Article : Google Scholar : PubMed/NCBI

Galle E, Thienpont B, Cappuyns S, Venken T, Busschaert P, Van Haele M, Van Cutsem E, Roskams T, van Pelt J, Verslype C, et al: DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clin Epigenetics. 12:272020. View Article : Google Scholar : PubMed/NCBI

Leon G, MacDonagh L, Finn SP, Cuffe S and Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol Ther. 158:71–90. 2016. View Article : Google Scholar

Vitale D, Kumar Katakam S, Greve B, Jang B, Oh ES, Alaniz L and Götte M: Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. FEBS J. 286:2870–2882. 2019. View Article : Google Scholar : PubMed/NCBI

Zhang H, Xu H, Ashby CR Jr, Assaraf YG, Chen ZS and Liu HM: Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev. 41:525–555. 2021. View Article : Google Scholar

Briz O, Perez-Silva L, Al-Abdulla R, Abete L, Reviejo M, Romero MR and Marin JJG: What 'the cancer genome atlas' database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs. Expert Opin Drug Metab Toxicol. 15:577–593. 2019. View Article : Google Scholar : PubMed/NCBI

He C, Sun Z, Hoffman RM, Yang Z, Jiang Y, Wang L and Hao Y: P-glycoprotein overexpression is associated with cisplatin resistance in human osteosarcoma. Anticancer Res. 39:1711–1718. 2019. View Article : Google Scholar : PubMed/NCBI

Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 455:152–162. 1976. View Article : Google Scholar : PubMed/NCBI

Ibrahim MAA, Abdeljawaad KAA, Jaragh-Alhadad LA, Oraby HF, Atia MAM, Alzahrani OR, Mekhemer GAH, Moustafa MF, Shawky AM, Sidhom PA and Abdelrahman AHM: Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: An in silico drug discovery study. J Biomol Struct Dyn. 1–16. 2023.Epub ahead of print.

Chang YT, Lin YC, Sun L, Liao WC, Wang CCN, Chou CY, Morris-Natschke SL, Lee KH and Hung CC: Wilforine resensitizes multidrug resistant cancer cells via competitive inhibition of P-glycoprotein. Phytomedicine. 71:1532392020. View Article : Google Scholar : PubMed/NCBI

Liu M, Xu C, Qin X, Liu W, Li D, Jia H, Gao X, Wu Y, Wu Q, Xu X, et al: DHW-221, a dual PI3K/mTOR inhibitor, overcomes multidrug resistance by targeting P-glycoprotein (P-gp/ABCB1) and Akt-mediated FOXO3a nuclear translocation in non-small cell lung cancer. Front Oncol. 12:8736492022. View Article : Google Scholar : PubMed/NCBI

Liu T, Wei R, Zhang Y, Chen W and Liu H: Association between NF-κB expression and drug resistance of liver cancer. Oncol Lett. 17:1030–1034. 2019.PubMed/NCBI

Liu Y, Cao F, Xia F, Li J, Dong X, Guo Y, Zhang J, Zhao Q and Liu Y: Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2/COX2/MDR1 axis. Cancer Med. 12:10768–10780. 2023. View Article : Google Scholar : PubMed/NCBI

Jeddi F, Soozangar N, Sadeghi MR, Somi MH, Shirmohamadi M, Eftekhar-Sadat AT and Samadi N: Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer. Biomed Pharmacother. 97:286–292. 2018. View Article : Google Scholar

Chen Q, Liu X, Luo Z, Wang S, Lin J, Xie Z, Li M, Li C, Cao H, Huang Q, et al: Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression. J Cell Physiol. 234:6611–6623. 2019. View Article : Google Scholar

Mai L, Luo M, Wu JJ, Yang JH and Hong LY: The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells. Neoplasma. 66:776–784. 2019. View Article : Google Scholar : PubMed/NCBI

Ren H, Wang Z, Chen Y, Liu Y, Zhang S, Zhang T and Li Y: SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway. Onco Targets Ther. 12:2585–2594. 2019. View Article : Google Scholar : PubMed/NCBI

Yamamoto M, Suzuki S, Togashi K, Sanomachi T, Seino S, Kitanaka C and Okada M: AS602801 sensitizes ovarian cancer stem cells to paclitaxel by down-regulating MDR1. Anticancer Res. 39:609–617. 2019. View Article : Google Scholar : PubMed/NCBI

Gao J, Hou D, Hu P and Mao G: Curcumol increases the sensitivity of colon cancer to 5-FU by regulating Wnt/β-catenin signaling. Transl Cancer Res. 10:2437–2450. 2021. View Article : Google Scholar

Li M, Li ZH, Song J, Li X, Zhai P, Mu X, Qiu F and Yao L: miR-205 Reverses MDR-1 mediated doxorubicin resistance via PTEN in human liver cancer HepG2 cells. Cell J. 24:112–119. 2022.PubMed/NCBI

Zhang L, Li Y, Hu C, Chen Y, Chen Z, Chen ZS, Zhang JY and Fang S: CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. Mol Cancer. 21:1032022. View Article : Google Scholar : PubMed/NCBI

Wan Y, Chen Z, Wang Y, Zhao W, Pei Z, Pu L, Lv Y, Li J, Li J and Pei Y: A hyaluronic acid modified cuprous metal-organic complex for reversing multidrug resistance via redox dyshomeostasis. Carbohydr Polym. 311:1207622023. View Article : Google Scholar : PubMed/NCBI

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Abou-Alfa GK: Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Netw. 7:397–403. 2009. View Article : Google Scholar : PubMed/NCBI

Xia X, Wang Q, Ye T, Liu Y, Liu D, Song S and Zheng C: NRF2/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells. Fundam Clin Pharmacol. 34:41–50. 2020. View Article : Google Scholar

Yuan P, Zheng A and Tang Q: Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway. Cell Biol Int. 44:1503–1513. 2020. View Article : Google Scholar : PubMed/NCBI

Mou SJ, Yang PF, Liu YP, Xu N, Jiang WW and Yue WJ: BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci. 242:1171772020. View Article : Google Scholar

Fang Z, Chen W, Yuan Z, Liu X and Jiang H: LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 101:536–542. 2018. View Article : Google Scholar : PubMed/NCBI

Zhao L, Bin S, He HL, Yang JM, Pu YC, Gao CH, Wang H and Wang BL: Sodium butyrate increases P-gp expression in lung cancer by upregulation of STAT3 and mRNA stabilization of ABCB1. Anticancer Drugs. 29:227–233. 2018. View Article : Google Scholar : PubMed/NCBI

Zhu J, Hu W, Zhang Y, Du P, Xiao W and Li Y: Comparison of survival outcomes of chemotherapy plus surgery vs chemotherapy alone for patients with isolated liver metastases from gallbladder carcinoma. Am Surg. 89:676–684. 2023. View Article : Google Scholar

Wu D, Liu L, Yan X, Wang C, Wang Y, Han K, Lin S, Gan Z and Min D: Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein. Oncotarget. 8:63857–63870. 2017. View Article : Google Scholar : PubMed/NCBI

Yang JZ, Huang LH, Chen R, Meng LJ, Gao YY, Ji QY and Wang Y: LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells. Oncol Lett. 15:250–256. 2018.PubMed/NCBI

Liu S, Chen S, Yuan W, Wang H, Chen K and Li D and Li D: PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. Oncotarget. 8:99901–99912. 2017. View Article : Google Scholar : PubMed/NCBI

Chen S, Wang H, Li Z, You J, Wu QW, Zhao C, Tzeng CM and Zhang ZM: Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. Br J Cancer. 119:182–192. 2018. View Article : Google Scholar : PubMed/NCBI

Lim JS, Jung GY and Park SY: Nkx-2.5 regulates MDR1 expression via its upstream promoter in breast cancer cells. J Korean Med Sci. 34:e1002019. View Article : Google Scholar : PubMed/NCBI

Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M and Bendas G: β₁-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta Mol Cell Res. 1867:1186632020. View Article : Google Scholar

Li G, Guo J, Shen BQ, Yadav DB, Sliwkowski MX, Crocker LM, Lacap JA and Phillips GDL: Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther. 17:1441–1453. 2018. View Article : Google Scholar : PubMed/NCBI

Tang H, Zeng L, Wang J, Zhang X, Ruan Q, Wang J, Cui S and Yang D: Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer. Oncotarget. 8:82842–82853. 2017. View Article : Google Scholar : PubMed/NCBI

Deng XJ, Zheng HL, Ke XQ, Deng M, Ma ZZ, Zhu Y and Cui YY: Hsa-miR-34a-5p reverses multidrug resistance in gastric cancer cells by targeting the 3′-UTR of SIRT1 and inhibiting its expression. Cell Signal. 84:1100162021. View Article : Google Scholar

Xu YD, Shang J, Li M and Zhang YY: LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. Eur Rev Med Pharmacol Sci. 23:2794–2802. 2019.PubMed/NCBI

Zhang X, Bo P, Liu L, Zhang X and Li J: Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother. 92:580–585. 2017. View Article : Google Scholar : PubMed/NCBI

Tan B, Li Y, Zhao Q, Fan L and Wang D: ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185. Biosci Rep. 38:BSR201810232018. View Article : Google Scholar : PubMed/NCBI

Yan X, Zhao J and Zhang R: Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 80:395–403. 2017. View Article : Google Scholar : PubMed/NCBI

Gao Z, Li Z, Liu Y and Liu Z: Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression. Mol Genet Genomic Med. 7:e5542019. View Article : Google Scholar : PubMed/NCBI

Du J, He Y, Li P, Wu W, Chen Y and Ruan H: IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 81:1111–1119. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang S, Chatterjee T, Godoy C, Wu L, Liu QJ and Carmon KS: GPR56 drives colorectal tumor growth and promotes drug resistance through upregulation of MDR1 expression via a RhoA-mediated mechanism. Mol Cancer Res. 17:2196–2207. 2019. View Article : Google Scholar : PubMed/NCBI

Sui M, Yang H, Guo M, Li W, Gong Z, Jiang J and Li P: Cajanol sensitizes A2780/Taxol cells to paclitaxel by inhibiting the PI3K/Akt/NF-κB signaling pathway. Front Pharmacol. 12:7833172021. View Article : Google Scholar

Zhao P, Wang S, Jiang J, Liu H, Zhu X, Zhao N, Li J, Yin Y, Pan X, Yang X, et al: TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1-NF-κB and-AP-1 pathways. Mol Immunol. 101:471–478. 2018. View Article : Google Scholar : PubMed/NCBI

Song W, Liang C, Sun Y, Morii S, Yomogida S, Isaji T, Fukuda T, Hang Q, Hara A, Nakano M and Gu J: Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway. J Biol Chem. 299:1030512023. View Article : Google Scholar

Liu K, Song J, Yan Y, Zou K, Che Y, Wang B, Li Z, Yu W, Guo W, Zou L, et al: Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway. Transl Oncol. 14:1008762021. View Article : Google Scholar

Liu RM, Xu P, Chen Q, Feng SL and Xie Y: A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo. Phytomedicine. 79:1533422020. View Article : Google Scholar : PubMed/NCBI

Wang H, Jia XH, Chen JR, Wang JY and Li YJ: Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep. 35:3659–3668. 2016. View Article : Google Scholar : PubMed/NCBI

Satonaka H, Ishida K, Takai M, Koide R, Shigemasa R, Ueyama J, Ishikawa T, Hayashi K, Goto H and Wakusawa S: (-)-Epigallocatechin-3-gallate down-regulates doxorubicin-induced overexpression of P-glycoprotein through the coordinate inhibition of PI3K/Akt and MEK/ERK signaling pathways. Anticancer Res. 37:6071–6077. 2017.PubMed/NCBI

Ding Y, Zhen Z, Nisar MA, Ali F, Din RU, Khan M, Mughal TA, Alam G, Liu L and Saleem MZ: Sesquiterpene lactones attenuate paclitaxel resistance via inhibiting MALAT1/STAT3/FUT4 Axis and P-glycoprotein transporters in lung cancer cells. Front Pharmacol. 13:7956132022. View Article : Google Scholar

Wang PP, Luan JJ, Xu WK, Wang L, Xu DJ, Yang CY, Zhu YH and Wang YQ: Astragaloside IV downregulates the expression of MDR1 in Bel-7402/FU human hepatic cancer cells by inhibiting the JNK/c-Jun/AP-1 signaling pathway. Mol Med Rep. 16:2761–2766. 2017. View Article : Google Scholar : PubMed/NCBI

Qin T, Zhu W, Kan X, Li L and Wu D: Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384. J Bone Oncol. 34:100429–34. 2022. View Article : Google Scholar

Li L, Fu Q, Xia M, Xin L, Shen H, Li G, Ji G, Meng Q and Xie Y: Inhibition of P-glycoprotein mediated efflux in Caco-2 cells by phytic acid. J Agric Food Chem. 66:988–998. 2018. View Article : Google Scholar

Mirzaei SA, Reiisi S, Ghiasi Tabari P, Shekari A, Aliakbari F, Azadfallah E and Elahian F: Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells. Sci Rep. 8:34462018. View Article : Google Scholar : PubMed/NCBI

Shen X, Chen G, Zhu G and Fong WF: (+/−)-3′-O, 4′-O-dicynnamoyl-cis-khellactone, a derivative of (+/−)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Bioorg Med Chem. 14:7138–7145. 2006. View Article : Google Scholar : PubMed/NCBI

Bai Z, Zhou Q, Zhu H, Ye X, Wu P and Ma L: QTMP, a novel thiourea polymer, causes DNA damage to exert anticancer activity and overcome multidrug resistance in colorectal cancer cells. Front Oncol. 11:6676892021. View Article : Google Scholar : PubMed/NCBI

Gao M, Liu T, Li J, Guan Q, Wang H, Yan S, Li Z, Zuo D, Zhang W and Wu Y: YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells. Toxicol In Vitro. 69:1049712020. View Article : Google Scholar : PubMed/NCBI

Wu CP, Murakami M, Wu YS, Chi YC, Hsiao SH, Huang YH, Hung TH and Ambudkar SV: Branebrutinib (BMS-986195), a bruton's tyrosine kinase inhibitor, resensitizes P-glycoprotein-overexpressing multidrug-resistant cancer cells to chemotherapeutic agents. Front Cell Dev Biol. 9:6995712021. View Article : Google Scholar : PubMed/NCBI

Podolski-Renić A, Dinić J, Stanković T, Tsakovska I, Pajeva I, Tuccinardi T, Botta L, Schenone S and Pešić M: New therapeutic strategy for overcoming multidrug resistance in cancer cells with pyrazolo[3,4-d]pyrimidine tyrosine kinase inhibitors. Cancers (Basel). 13:53082021. View Article : Google Scholar

Wu CP, Hung TH, Lusvarghi S, Chu YH, Hsiao SH, Huang YH, Chang YT and Ambudkar SV: The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochem Pharmacol. 188:1145162021. View Article : Google Scholar : PubMed/NCBI

Zhang L, Ye B, Lin Y, Li YD, Wang JQ, Chen Z, Ping FF and Chen ZS: Ribociclib inhibits P-gp-mediated multidrug resistance in human epidermoid carcinoma cells. Front Pharmacol. 13:8671282022. View Article : Google Scholar : PubMed/NCBI

Laiolo J, Barbieri CL, Joray MB, Lanza PA, Palacios SM, Vera DMA and Carpinella MC: Plant extracts and betulin from Ligaria cuneifolia inhibit P-glycoprotein function in leukemia cells. Food Chem Toxicol. 147:1119222021. View Article : Google Scholar

Liu Z, Wen X, Wang G and Zhou Y: Involvement of P-gp on reversing multidrug resistance effects of 23-hydroxybetulinic acid on chemotherapeutic agents. Front Pharmacol. 12:7967452021. View Article : Google Scholar :

Yang T, Wang S, Li H, Zhao Q, Yan S, Dong M, Liu D, Chen X and Li R: Lathyrane diterpenes from Euphorbia lathyris and the potential mechanism to reverse the multi-drug resistance in HepG2/ADR cells. Biomed Pharmacother. 121:1096632020. View Article : Google Scholar

Qian J, Xia M, Liu W, Li L, Yang J, Mei Y, Meng Q and Xie Y: Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Eur J Pharmacol. 852:231–243. 2019. View Article : Google Scholar : PubMed/NCBI

Teng YN, Lin KI, Lin YC, Thang TD, Lan YH and Hung CC: A novel flavonoid from Fissistigma cupreonitens, 5-hydroxy-7,8-dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance. Phytomedicine. 85:1535282021. View Article : Google Scholar

Min H, Niu M, Zhang W, Yan J, Li J, Tan X, Li B, Su M, Di B and Yan F: Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein. PLoS One. 12:e01879712017. View Article : Google Scholar : PubMed/NCBI

Pellegrini E, Multari G, Gallo FR, Vecchiotti D, Zazzeroni F, Condello M and Meschini S: A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells. Toxicol Appl Pharmacol. 434:1158162022. View Article : Google Scholar

Sagnou M, Novikov FN, Ivanova ES, Alexiou P, Stroylov VS, Titov IY, Tatarskiy VV, Vagida MS, Pelecanou M, Shtil AA and Chilov GG: Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin. Eur J Med Chem. 198:1123312020. View Article : Google Scholar : PubMed/NCBI

Creemers SG, van Koetsveld PM, De Herder WW, Dogan F, Franssen GJH, Feelders RA and Hofland LJ: MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. Endocr Relat Cancer. 26:367–378. 2019. View Article : Google Scholar : PubMed/NCBI

Wang SQ, Teng QX, Wang S, Lei ZN, Hu HH, Lv HF, Chen BB, Wang JZ, Shi XJ, Xu WF, et al: Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharm Sin B. 12:3263–3280. 2022. View Article : Google Scholar : PubMed/NCBI

Dei S, Coronnello M, Bartolucci G, Manetti D, Romanelli MN, Udomtanakunchai C, Salerno M and Teodori E: Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents. Eur J Med Chem. 147:7–20. 2018. View Article : Google Scholar : PubMed/NCBI

Qiu Q, Zou F, Li H, Shi W, Zhou D, Zhang P, Li T, Yin Z, Cai Z, Jiang Y, et al: Structure-based discovery of pyrimidine aminobenzene derivatives as potent oral reversal agents against P-gp- and BCRP-mediated multidrug resistance. J Med Chem. 64:6179–6197. 2021. View Article : Google Scholar : PubMed/NCBI

Li YS, Yang X, Zhao DS, Cai Y, Huang Z, Wu R, Wang SJ, Liu GJ, Wang J, Bao XZ, et al: Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell. Eur J Med Chem. 216:1133362021. View Article : Google Scholar : PubMed/NCBI

Yuan S, Wang B, Dai QQ, Zhang XN, Zhang JY, Zuo JH, Liu H, Chen ZS, Li GB, Wang S, et al: Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors. J Med Chem. 64:14895–14911. 2021. View Article : Google Scholar : PubMed/NCBI

Wang H, Wang X, Liao A and Liu Z: Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway. Mol Cell Biochem. 433:141–148. 2017. View Article : Google Scholar : PubMed/NCBI

Snyder S, Murundi S, Crawford L and Putnam D: Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate. J Control Release. 317:291–299. 2020. View Article : Google Scholar

Zhang H, Bian S, Xu Z, Gao M, Wang H, Zhang J, Zhang M, Ke Y, Wang W, Chen ZS and Xu H: The effect and mechanistic study of encequidar on reversing the resistance of SW620/AD300 cells to doxorubicin. Biochem Pharmacol. 205:1152582022. View Article : Google Scholar : PubMed/NCBI

Xu SW, Law BYK, Qu SLQ, Hamdoun S, Chen J, Zhang W, Guo JR, Wu AG, Mok SWF, Zhang DW, et al: SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells. Pharmacol Res. 153:1046602020. View Article : Google Scholar : PubMed/NCBI

Rauf A, Uddin G, Raza M, Ahmad B, Jehan N, Siddiqui BS, Molnar J, Csonka A and Szabo D: Reversal of multidrug resistance in mouse lymphoma cells by extracts and flavonoids from Pistacia integerrima. Asian Pac J Cancer Prev. 17:51–55. 2016. View Article : Google Scholar : PubMed/NCBI

Giorgi C, Gasser UE, Lafont ME, Holzgang HE and Thalhammer VF: Inhibition of chemoresistance in primary tumor cells by Camellia sinensis non fermentatum extract noviphenone (NPE^®). Anticancer Res. 39:4101–4110. 2019. View Article : Google Scholar : PubMed/NCBI

Kawami M, Yamada Y, Issarachot O, Junyaprasert VB, Yumoto R and Takano M: P-gp modulating effect of Azadirachta indica extract in multidrug-resistant cancer cell lines. Pharmazie. 73:104–109. 2018.PubMed/NCBI

Zheng Y, Su C, Zhao L and Shi Y: mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy. J Nanobiotechnology. 15:662017. View Article : Google Scholar : PubMed/NCBI

Chen Z, Pan T, Jiang D, Jin L, Geng Y, Feng X, Shen A and Zhang L: The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the Wnt/β-catenin signaling pathway. Mol Ther Nucleic Acids. 19:1434–1448. 2020. View Article : Google Scholar : PubMed/NCBI

Han Z and Shi L: Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 495:947–953. 2018. View Article : Google Scholar

Kang Y, Zhang S, Cao W, Wan D and Sun L: Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/β-catenin pathway. Biosci Rep. 40:BSR201934502020. View Article : Google Scholar

Zou H and Li H: Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells. Exp Ther Med. 18:4510–4516. 2019.PubMed/NCBI

Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang J, Zhu J, Chen L, Bao X, Liu Y, et al: miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 21:1929–1943. 2017. View Article : Google Scholar : PubMed/NCBI

Zhao Y, Qi X, Chen J, Wei W, Yu C, Yan H, Pu M, Li Y, Miao L, Li C and Ren J: The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Cancer Lett. 408:102–111. 2017. View Article : Google Scholar : PubMed/NCBI

Yi D, Xu L, Wang R, Lu X and Sang J: miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int. 43:12–21. 2019. View Article : Google Scholar

Zheng SZ, Sun P, Wang JP, Liu Y, Gong W and Liu J: MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World J Gastroenterol. 25:2752–2762. 2019. View Article : Google Scholar : PubMed/NCBI

Wei S, Gao J, Zhang M, Dou Z, Li W and Zhao L: Dual delivery nanoscale device for miR-451 and adriamycin co-delivery to combat multidrug resistant in bladder cancer. Biomed Pharmacother. 122:1094732020. View Article : Google Scholar : PubMed/NCBI

Kenworthy R, Bosco DB, DeLigio JT and Zorio DAR: Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression. Cancer Biol Ther. 19:181–187. 2018. View Article : Google Scholar :

Wang S, Guo J, Mo Z, Shi X and Qu C: Clinical significance and correlation of miR-200c and P-gp expression in gastric cancer and the effects on multidrug resistance. J Gastrointest Oncol. 13:581–592. 2022. View Article : Google Scholar : PubMed/NCBI

Cao F and Yin LX: miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol. 106:34–43. 2019. View Article : Google Scholar

Sousa D, Matthiesen R, Lima RT and Vasconcelos MH: Deep sequencing analysis reveals distinctive non-coding RNAs when comparing tumor multidrug-resistant cells and extracellular vesicles with drug-sensitive counterparts. Cancers (Basel). 12:2002020. View Article : Google Scholar : PubMed/NCBI

Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, Safa A and Yosefi B: miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 880:1731382020. View Article : Google Scholar : PubMed/NCBI

Xie B, Li L, Zhang Z, Zhao L, Cheng J, Zhou C, Cheng J, Yan J, Chen J, Yi J, et al: MicroRNA-1246 by targeting AXIN2 and GSK-3β overcomes drug resistance and induces apoptosis in chemo-resistant leukemia cells. J Cancer. 12:4196–4208. 2021. View Article : Google Scholar :

Kara G, Calin GA and Ozpolat B: RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 182:1141132022. View Article : Google Scholar : PubMed/NCBI

Yalamarty SSK, Filipczak N, Li X, Pathrikar TV, Cotter C and Torchilin VP: Co-delivery of siRNA and chemotherapeutic drug using 2C5 antibody-targeted dendrimer-based mixed micelles for multidrug resistant cancers. Pharmaceutics. 14:14702022. View Article : Google Scholar : PubMed/NCBI

Wang C, Guan W, Peng J, Chen Y, Xu G and Dou H: Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors. Acta Biomater. 103:247–258. 2020. View Article : Google Scholar

Jiang Y, Liu Y, Wang M, Li Z, Su L, Xu X, Xing C, Li J, Lin L, Lu C and Yang H: siRNA-based carrier-free system for synergistic chemo/chemodynamic/RNAi therapy of drug-resistant tumors. ACS Appl Mater Interfaces. 14:361–372. 2022. View Article : Google Scholar

Yang X, Wang Y, Chen S, Zhang S and Cui C: Cetuximab-modified human serum albumin nanoparticles co-loaded with doxorubicin and MDR1 siRNA for the treatment of drug-resistant breast tumors. Int J Nanomedicine. 16:7051–7069. 2021. View Article : Google Scholar : PubMed/NCBI

Liu H, Ma D, Chen J, Ye L, Li Y, Xie Y, Zhao X, Zou H, Chen X, Pu J and Liu P: A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer. Nano Res. 15:6306–6314. 2022. View Article : Google Scholar

Wu J, Wang Q, Dong X, Xu M, Yang J, Yi X, Chen B, Dong X, Wang Y, Lou X, et al: Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. Theranostics. 11:3710–3724. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang J, Du Z, Pan S, Shi M, Li J, Yang C, Hu H, Qiao M, Chen D and Zhao X: Overcoming multidrug resistance by codelivery of MDR1-targeting siRNA and doxorubicin using EphA10-mediated pH-sensitive lipoplexes: In vitro and in vivo evaluation. ACS Appl Mater Interfaces. 10:21590–21600. 2018. View Article : Google Scholar : PubMed/NCBI

Cao X, Li R, Xiong H, Su J, Guo C, An T, Zong H and Zhao R: Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein. Eur J Med Chem. 221:1135202021. View Article : Google Scholar : PubMed/NCBI

Liu ZL, Jin BJ, Cheng CG, Zhang FX, Wang SW, Wang Y and Wu B: Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway. Eur Rev Med Pharmacol Sci. 21:5370–5377. 2017.PubMed/NCBI

Ji L, Liu X, Zhang S, Tang S, Yang S, Li S, Qi X, Yu S, Lu L, Meng X and Liu Z: The novel triazolonaphthalimide derivative LSS-11 synergizes the anti-proliferative effect of paclitaxel via STAT3-dependent MDR1 and MRP1 downregulation in chemoresistant lung cancer cells. Molecules. 22:18222017. View Article : Google Scholar : PubMed/NCBI

Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, Hu C, Liao D, Zhang W and Chen ZS: The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 19:102020. View Article : Google Scholar

Liu T, Peng Y, Li X, Liu L, Liu F and He L: A novel delocalized lipophilic cation-chlorambucil conjugate inhibits P-glycoprotein in HepG2/ADM cells. Bioorg Med Chem. 25:5461–5467. 2017. View Article : Google Scholar : PubMed/NCBI

Ganesan M, Kanimozhi G, Pradhapsingh B, Khan HA, Alhomida AS, Ekhzaimy A, Brindha GR and Prasad NR: Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. Biomed Pharmacother. 139:1116322021. View Article : Google Scholar : PubMed/NCBI

Li Y, Li X, Lu Y, Chaurasiya B, Mi G, Shi D, Chen D, Webster TJ, Tu J and Shen Y: Co-delivery of Poria cocos extract and doxorubicin as an 'all-in-one' nanocarrier to combat breast cancer multidrug resistance during chemotherapy. Nanomedicine. 23:1020952020. View Article : Google Scholar

Ye Q, Liu K, Shen Q, Li Q, Hao J, Han F and Jiang RW: Reversal of multidrug resistance in cancer by multi-functional flavonoids. Front Oncol. 9:4872019. View Article : Google Scholar : PubMed/NCBI

Fang Y, Liang F, Xia M, Cao W, Pan S, Wu T and Xu X: Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. Food Chem Toxicol. 155:1123812021. View Article : Google Scholar : PubMed/NCBI

Kong W, Ling X, Chen Y, Wu X, Zhao Z, Wang W, Wang S, Lai G and Yu Z: Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway. Int J Mol Med. 45:1213–1224. 2020.PubMed/NCBI

La X, Zhang L, Li Z, Li H and Yang Y: (-)-Epigallocatechin gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-κB/miR-155-5p/MDR1 pathway. J Agric Food Chem. 67:2510–2518. 2019. View Article : Google Scholar : PubMed/NCBI

Mohana S, Ganesan M, Rajendra Prasad N, Ananthakrishnan D and Velmurugan D: Flavonoids modulate multidrug resistance through wnt signaling in P-glycoprotein overexpressing cell lines. BMC Cancer. 18:11682018. View Article : Google Scholar : PubMed/NCBI

Wang ZD, Wang RZ, Xia YZ, Kong LY and Yang L: Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells. Chin J Nat Med. 16:20–28. 2018.PubMed/NCBI

Wang F, Huang N, Yang Q, Liu J and Chen J: Reversal of doxorubicin-resistance by Salvia miltiorrhiza ligustrazine in the SHG44/doxorubicin glioma drug-resistant cell line. Oncol Lett. 14:4708–4714. 2017. View Article : Google Scholar : PubMed/NCBI

Zhou P, Zhang R, Wang Y, Xu D, Zhang L, Qin J, Su G, Feng Y, Chen H, You S, et al: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. Oncotarget. 8:111144–111160. 2017. View Article : Google Scholar

Zhou X, Jin N and Chen B: Tetrandrine overcomes drug resistance mediated by bone marrow microenvironment by regulating the expression of P-glycoprotein in acute leukemia. Hematology. 27:274–279. 2022. View Article : Google Scholar : PubMed/NCBI

Qian K, Tang CY, Chen LY, Zheng S, Zhao Y, Ma LS, Xu L, Fan LH, Yu JD, Tan HS, et al: Berberine reverses breast cancer multidrug resistance based on fluorescence pharmacokinetics in vitro and in vivo. ACS Omega. 6:10645–10654. 2021. View Article : Google Scholar : PubMed/NCBI

Huang CZ, Wang YF, Zhang Y, Peng YM, Liu YX, Ma F, Jiang JH and Wang QD: Cepharanthine hydrochloride reverses P-glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep. 38:2558–2564. 2017. View Article : Google Scholar : PubMed/NCBI

Liao D, Zhang W, Gupta P, Lei ZN, Wang JQ, Cai CY, Vera AA, Zhang L, Chen ZS and Yang DH: Tetrandrine interaction with ABCB1 reverses multidrug resistance in cancer cells through competition with anti-cancer drugs followed by downregulation of ABCB1 expression. Molecules. 24:43832019. View Article : Google Scholar : PubMed/NCBI

Quarti J, Torres DNM, Ferreira E, Vidal RS, Casanova F, Chiarini LB, Fialho E and Rumjanek VM: Selective cytotoxicity of piperine over multidrug resistance leukemic cells. Molecules. 26:9342021. View Article : Google Scholar : PubMed/NCBI

Wang SQ, Li X, Wang XN and Lou HX: Reversal of P-glycoprotein-mediated multidrug resistance in human leukemia cell line K562/A02 by archangelicin. Chin J Nat Med. 9:146–150. 2011.

Sharma P, Tyagi A, Bhansali P, Pareek S, Singh V, Ilyas A, Mishra R and Poddar NK: Saponins: Extraction, bio-medicinal properties and way forward to anti-viral representatives. Food Chem Toxicol. 150:1120752021. View Article : Google Scholar : PubMed/NCBI

Li Y, Sun Y, Tang T, Niu Y, Li X, Xie M, Jin H and Mei Q: Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells. J Ethnopharmacol. 232:47–54. 2019. View Article : Google Scholar

Niu X, Shi Y, Li Q, Chen H, Fan X, Yu Y, Lv C and Lu J: Ginsenoside Rb₁ for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1. Phytomedicine. 115:1547762023. View Article : Google Scholar

Li J, Zheng L, Wang R, Sun D, Liang S, Wu J, Liu Y, Tian X, Li T, Yang Y and Han L: Synergistic combination of sodium aescinate-stabilized, polymer-free, twin-like nanoparticles to reverse paclitaxel resistance. Int J Nanomedicine. 15:5839–5853. 2020. View Article : Google Scholar : PubMed/NCBI

Huang C, Xu D, Xia Q, Wang P, Rong C and Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by astragaloside II. J Pharm Pharmacol. 64:1741–1750. 2012. View Article : Google Scholar : PubMed/NCBI

Wang PP, Xu DJ, Huang C, Wang WP and Xu WK: Astragaloside IV reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines. Mol Med Rep. 9:2131–2137. 2014. View Article : Google Scholar : PubMed/NCBI

Liu GW, Liu YH, Jiang GS and Ren WD: The reversal effect of ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell. 31:189–198. 2018. View Article : Google Scholar : PubMed/NCBI

Liu C, Gong Q, Chen T, Lv J, Feng Z, Liu P and Deng Z: Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors. Oncol Lett. 15:4376–4382. 2018.PubMed/NCBI

Sadava D and Kane SE: Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett. 339:102–106. 2013. View Article : Google Scholar : PubMed/NCBI

Dobiasová S, Řehořová K, Kučerová D, Biedermann D, Káňová K, Petrásková L, Koucká K, Václavíková R, Valentová K, Ruml T, et al: Multidrug resistance modulation activity of silybin derivatives and their anti-inflammatory potential. Antioxidants (Basel). 9:4552020. View Article : Google Scholar : PubMed/NCBI

Zhang ZL, Jiang QC and Wang SR: Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Breast Cancer. 25:233–242. 2018. View Article : Google Scholar

Liao XZ, Gao Y, Sun LL, Liu JH, Chen HR, Yu L, Chen ZZ, Chen WH and Lin LZ: Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway. Phytother Res. 34:1142–1153. 2020. View Article : Google Scholar : PubMed/NCBI

Muthusamy G, Gunaseelan S and Prasad NR: Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-κB signaling pathway. J Nutr Biochem. 63:62–71. 2019. View Article : Google Scholar

Oh SS, Lee KW, Madhi H, Jeong JW, Park S, Kim M, Lee Y, Han HT, Hwangbo C, Yoo J and Kim KD: Cordycepin resensitizes T24R2 cisplatin-resistant human bladder cancer cells to cisplatin by inactivating Ets-1 dependent MDR1 transcription. Int J Mol Sci. 21:17102020. View Article : Google Scholar : PubMed/NCBI

Sawicka E, Saczko J, Kulbacka J, Szydełko M, Szymańska B and Piwowar A: The influence of interaction between cadmium with 17β-estradiol, 2-methoxyestradiol and 16α-hydroxyestrone on viability and P-glycoprotein in ovarian cancer cell line. Int J Mol Sci. 23:26282022. View Article : Google Scholar

Ding Y, Fan J, Fan Z and Zhang K: γ-Tocotrienol reverses multidrug resistance of breast cancer cells through the regulation of the γ-Tocotrienol-NF-κB-P-gp axis. J Steroid Biochem Mol Biol. 209:1058352021. View Article : Google Scholar

Fujihara T, Mizobuchi Y, Nakajima K, Kageji T, Matsuzaki K, Kitazato KT, Otsuka R, Hara K, Mure H, Okazaki T, et al: Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. J Neurooncol. 139:323–332. 2018. View Article : Google Scholar : PubMed/NCBI

Norouzi-Barough L, Sarookhani M, Salehi R, Sharifi M and Moghbelinejad S: CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line. Iran J Basic Med Sci. 21:181–187. 2018.PubMed/NCBI

Peng H, Qiao L, Shan G, Gao M, Zhang R, Yi X and He X: Stepwise responsive carboxymethyl chitosan-based nanoplatform for effective drug-resistant breast cancer suppression. Carbohydr Polym. 291:1195542022. View Article : Google Scholar : PubMed/NCBI

Teng YN, Wang CCN, Liao WC, Lan YH and Hung CC: Caffeic acid attenuates multi-drug resistance in cancer cells by inhibiting efflux function of human P-glycoprotein. Molecules. 25:2472020. View Article : Google Scholar : PubMed/NCBI

Ma Y, Wen J, Wang J, Wang C, Zhang Y, Zhao L, Li J and Feng X: Asiaticoside antagonizes proliferation and chemotherapeutic drug resistance in hepatocellular carcinoma (HCC) cells. Med Sci Monit. 26:e9244352020. View Article : Google Scholar : PubMed/NCBI